Related Experiment Video
Updated: Oct 20, 2025

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair?
Lize Evens1, Hanne Beliën1, Sarah D'Haese1
1UHasselt-Hasselt University, BIOMED-Biomedical Research Institute, Agoralaan, 3590 Diepenbeek, Belgium.
Insights
Pyridoxamine (PM) did not improve cardiac regeneration in rats after myocardial infarction (MI) when combined with cardiac atrial appendage stem cells (CASCs). While PM reduced advanced glycation end products (AGEs), it did not enhance the benefits of CASCs therapy for heart repair.
Area of Science:
- Cardiology
- Regenerative Medicine
- Biochemistry
Background:
- Myocardial infarction (MI) leads to irreversible cardiomyocyte loss and heart failure progression.
- Current therapies for MI are insufficient for cardiac regeneration.
- Cardiac atrial appendage stem cells (CASCs) show promise for cellular therapy post-MI.
Purpose of the Study:
- To investigate if pyridoxamine (PM) enhances CASC transplantation efficacy after MI.
- To determine if PM reduces advanced glycation end products (AGEs) in the cardiac environment.
- To assess PM's impact on cardiac function and regeneration post-MI.
Main Methods:
- MI induced in rats via coronary artery ligation.
- Groups: No therapy, CASCs transplantation, CASCs + PM treatment.
- Evaluated cardiac function, infarct size, collagen deposition, and cardiomyocyte contractility.
Main Results:
- CASCs transplantation improved cardiac function and reduced infarct size.
- CASCs prevented deterioration of cardiomyocyte contractile properties.
- PM reduced cardiac AGEs but did not further improve cardiac outcomes compared to CASCs alone.
Conclusions:
- Pyridoxamine (PM) did not enhance the regenerative effects of CASCs transplantation post-MI.
- Reducing AGEs with PM did not improve cardiac outcomes in this stem cell therapy model.
- The role of AGEs in stem cell therapy efficacy after MI requires further investigation.
Abstract:
Myocardial infarction (MI) occurs when the coronary blood supply is interrupted. As a consequence, cardiomyocytes are irreversibly damaged and lost. Unfortunately, current therapies for MI are unable to prevent progression towards heart failure. As the renewal rate of cardiomyocytes is minimal, the optimal treatment should achieve effective cardiac regeneration, possibly with stem cells transplantation. In that context, our research group identified the cardiac atrial appendage stem cells (CASCs) as a new cellular therapy. However, CASCs are transplanted into a hostile environment, with elevated levels of advanced glycation end products (AGEs), which may affect their regenerative potential. In this study, we hypothesize that pyridoxamine (PM), a vitamin B6 derivative, could further enhance the regenerative capacities of CASCs transplanted after MI by reducing AGEs' formation. Methods and Results: MI was induced in rats by ligation of the left anterior descending artery. Animals were assigned to either no therapy (MI), CASCs transplantation (MI + CASCs), or CASCs transplantation supplemented with PM treatment (MI + CASCs + PM). Four weeks post-surgery, global cardiac function and infarct size were improved upon CASCs transplantation. Interstitial collagen deposition, evaluated on cryosections, was decreased in the MI animals transplanted with CASCs. Contractile properties of resident left ventricular cardiomyocytes were assessed by unloaded cell shortening. CASCs transplantation prevented cardiomyocyte shortening deterioration. Even if PM significantly reduced cardiac levels of AGEs, cardiac outcome was not further improved. Conclusion: Limiting AGEs' formation with PM during an ischemic injury in vivo did not further enhance the improved cardiac phenotype obtained with CASCs transplantation. Whether AGEs play an important deleterious role in the setting of stem cell therapy after MI warrants further examination.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inotropic Agents

